INTRODUCTION
The leukocyte has been implicated as a source of antihemophilic factor (AHF-factor VIII)' by several investigators (1, 2) . It has been known since 1911 that both normal and leukemic white cells contain material that enhanced in vitro clotting (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and recent studies have demonstrated this material to be tissue factor Received for publication 27 November 1972 and in revised form 29 January 1973. 'Abbrevations used in this paper: AHF, antihemophilic factor; CNP, control normal plasma; IBS, imadazole-saline buffer; PHA, phytohemagglutinin; PPD, purified protein derivative of tubercle bacillus; PTT, partial thromboplastin time; SBB, saline-barbital buffer. (15) (16) (17) (18) (19) . Nevertheless, reports of elevated factor VIII levels in blood from patients with leukocytosis (20) (21) (22) and of enhanced factor VIII levels in blood from a hemophilic child with acute lymphoblastic leukemia have been used as evidence that factor VIII is synthesized by white blood cells (2) .
In addition, the results of splenic perfusion studies (23) (24) (25) (26) , cell infusions (27) , and splenic transplantation in both animals and humans (28) (29) (30) were used to support the hypothesis that the spleen either stores, produces, or participates in the production of factor VIII. Since the spleen is predominantly a lymphoid organ, it seemed possible that lymphocytes played an important role in the increased plasma levels of factor VIII following splenic transplantation.
The conflicting data of some perfusion experiments (31) and the lack of more specific assays for both tissue factor and factor VIII have limited the interpretation of these earlier studies because the material assayed as factor VIII activity might have been tissue factor.
The purpose of this paper is to show that stimulated lymphocytes obtained from both normal individuals and patients with hemophilia A (classic hemophilia) contained tissue factor activity and that despite significant correction of factor VIII-deficient plasma in a coagulation assay no antihemophilic factor (AHF) antigen was demonstrated using a sensitive radioimmunoassay tech- nique.
METHODS
Lymphocyte cultures. Whole blood from normal subjects and patients with hemophilia A was collected in 50-ml portions by careful venipuncture, utilizing plastic syringes containing 1 ml sodium heparin (1,000 U.S.P. U/ml, Up-john Co., Kalamazoo, Mich.) and 5 ml of 6% Dextran solution in 5% dextrose in water (Pharmachem Corp., Bethlehem, Pa.). The lymphocytes were obtained by a modification of the method of Boyum (32) . The (36), and assays for factors II, V, VII, and X were performed in a prothrombin time system. Factor II-deficient reagent was prepared by a modification of the method of Pechet (37) . The reagent was prepared from citrated rather than oxalated serum (9 vol of human serum and 1 vol of sodium citrate, 3.8%). The only other modification of the original method utilized aluminum hydroxide (Amphojel, Wyeth Laboratories, Inc., Philadelphia, Pa.), 0.1 ml per 1.0 ml of citrated plasma, in place of barium sulfate. Factor V-deficient and factor X-deficient reagents were obtained from patients with the respective deficiency states. Factor VII-X complex reagent was prepared by the method of Bachmann, Duckert, and Koller (38) . Levels of factors VIII, IX, XI, and XII were determined in an activated partial thromboplastin assay system, modified from the method of Proctor and Rapaport (39) , utilizing Platelin plus Activator (Warner-Chilcott Laboratories). The lymphocyte suspensions (0.1 ml) and 0.1 ml of either a 1:10 dilution of CNP or saline-barbital buffer was preincubated with 0.1 ml of the respective factor-deficient substrate for 2 min at 370C. Platein plus Activator (0.1 ml) was then added, and the reagents were allowed to incubate for a further 5 min at 37°C. Calcium chloride (0.1 ml) was then added, and the clotting time was measured. All deficient substrates for the activated partial thromboplastin assay system were obtained from patients with the respective deficiency states. The presence of thrombin was evaluated by a modification of the method of Hardisty and Ingram (40) utilizing semipurified fibrinogen (Warner-Chilcott Laboratories); 0.2 ml of the fibrinogen was clotted with either 0.1 ml of the sample to be assayed or 0.1 ml of human thrombin (Ortho Pharmaceutical Corp.) as a standard at a concentration of 6.25 NIH U/ml of diluent.
The calcium chloride concentration used throughout the experiments was 0.025 M. Imidazole-saline buffer (IBS) for the tissue factor experiments was made with 0.05 M imidazole and 0.10 M sodium chloride and adjusted to pH 7.3 with concentrated hydrochloric acid. Saline-barbital buffer (SBB), used as diluent for all other coagulation tests, was prepared with 0.1 M sodium barbital, 0.15 M barbital, and 0.125 M sodium chloride and adjusted to pH 7.34. Control normal plasma was reconstituted fresh each day from 1.0 ml portions of a lyophilized pool (Dade CNP).
The procoagulant assays were performed on a Fibrometer (BioQuest Div., Becton, Dickinson & Co., Cockeysville, Md.) as were the prothrombin complex assays. The intrinsic system factors were assayed on a Clotek instrument (Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif.).
Tissue factor assay. Tissue factor was assayed by the two-stage method described by Nemerson (41) , using bovine serum eluate as a source for factors VII and X and bovine plasma as the substrate for activated factor X. Tissue factor activity of the various cultures was compared with the activity of the bovine brain standard used by Nemerson (41) .
Tissue factor antibody. Human placental tissue factor prepared by the method of Nemerson and Pitlick (42) was used to immunize New Zealand albino rabbits as described by Zeldis, Nemerson, Pitlick, and Lentz (43) . In brief, human placenta was homogenized and dehydrated by washing with large volumes of acetone followed by air-drying. The acetone powders were extracted with heptane-butanol (2: 1, 20 ml/g) to remove phospholipids and then extracted with 0.5 M NaCl to remove extraneous proteins. Following solubilization with 0.25%o sodium deoxycholate (Mann Research Labs, New York), the soluble material was brought to 30% saturation with solid ammonium sulfate and filtered, and the precipitate was discarded. The filtrate was brought to 60% saturation with solid ammonium sulfate, and the precipitate was collected by centrifugation. The apoprotein was then resuspended and dialyzed against imidazole-saline buffer (0.05 M imidazole, 0.375 M NaCl, pH 7.2) at 40C. The dialyzed material was concentrated by filtration (Diaflo XM-50 filter) and then gel filtered on Sepharose 6B (Pharmacia). Active fractions, as determined by the assay previously described (41), were pooled and rechromatographed on Sepharose 6B. Criteria for purity are detailed in the original reference (42) . The placental tissue factor had a specific activity of 10,000 U of tissue factor/mg protein. The rabbits were given an initial intradermal injection of 1 mg of the purified human tissue factor with complete Freund's adjuvant and subsequent biweekly injections of 100 ,ug of the antigen. Antiserum was harvested 2 wk after the third injection and then 2 wk after subsequent injections. The rabbit antibody neutralized tissue factor from human brain and placenta. Two precipitin lines appeared on immunodiffusion plates; these probably correspond to the two species previously noted (42) . The rabbit antibody neutralized coagulant activity of human brain acetone powders or purified placental tissue factor. Before use in the neutralization assays, both normal rabbit serum and rabbit antiserum to human tissue factor were absorbed with rabbit lung acetone powder (5 mg/ml), barium sulfate (100 mg/ml, three times), heated at 60°C for 30 min, then precipitated with i vol of saturated ammonium sulfate. The precipitate was resuspended in a volume of water equal to the starting volume and dialyzed overnight in IBS.
Inhibition of tissue factor activity. An acetone powder of human brain was prepared by the method of Nemerson (41) . This preparation was then homogenized and sonicated 15 s in IBS. This suspension was diluted until it was equivalent to 100 U of bovine tissue factor in the two-stage coagulation assay. The semipurified rabbit globulin described above was then serially diluted and incubated with the human brain thromboplastin at 370C for 30 min. For studies of inhibition of coagulant activity developed by the cultures, the globulin was used at that dilution which just inhibited all of the brain tissue factor. Globulin from the nonimmune rabbits served as a control for all experiments. The antigen and antibody were incubated in equal volumes for all determinations and compared with an equivalent dilution of the human brain tissue factor.
AHF antigen determination. AHF antigen was measured using a radioimmunoassay described in detail by Hoyer (44) . Rabbit anti-human AHF prepared by a minor modification of the method of Zimmerman, Ratnoff, and Powell (45) was purified and radiolabeled for use in this assay (46) . The 'MI-labeled IgG anti-AHF (0.5 ml) was incubated with S ml normal human plasma, and soluble antigenantibody complexes were separated by gel filtration of the mixture using Sepharose 6B (1.6 X 60 cm, 250C, flow rate of 20 ml/h, saline-barbital buffer). These complexes (void volume fractions) were then dissociated by dialysis using glycine-saline buffer, pH 2.4, prior to gel filtration on Sephadex G-200 (1.5 X 90 cm, 25°C, flow rate of 10 ml/h) equilibrated with the same buffer. The purified 'NI-labeled rabbit IgG was then dialyzed against SBB.
Material tested for AHF antigen was incubated with the anti-AHF, and bound, radiolabeled antibody was separated from free antibody by its insolubility in 25% saturated ammonium sulfate. The precipitated radioactivity was proportional to the amount of AHF antigen added, and a standard curve was prepared by plotting the percentage of 'I-anti-AHF counts precipitated (bound/total) vs. log microliters normal plasma. The least squares regression line for the normal plasma standard was used to calculate AHF antigen content for at least two dilutions of each test sample. The standard for antigen measurements was a plasma pool from 20 normal individuals stored at -70'C for less than 2 mo. The antibody-binding capacity of this pool was defined as being 100 antigen units/100 ml. RESULTS Lymphocytes obtained from normal individuals and harvested after 27 h of stimulation by either PHA or PPD generated significantly greater procoagulant activity, than control (unstimulated) cells in the one-stage factor VIII assay (Fig. 1) . 35 control cultures seldom shortened the substrate clotting time. Cells from the same individuals, stimulated either with PHA or PPD, consistently demonstrated shortening of the factor VIIIdeficient substrate clotting time by an average of 43 and 33, respectively. Similar results were obtained when cultures were evaluated from five hemophiliacs. Stimulated cells consistently exceeded control cells in the production of the procoagulant activity at the same cell concentration for all experiments described (Fig. 1) These data suggested that the lymphocyte procoagulant acted between factor VIII and factor X in the clotting cascade and led to an investigation of tissue factor. Using a previously described method (41) , tissue factor was indeed demonstrated in the stimulated cells (Fig. 3) (Fig. 4) . The apparent increased activity of the cells in this assay probably reflects species specificity in relation to the substrates since bovine plasma was used as the substrate in the tissue factor assay. Although it appeared that procoagulant activity persisted longer than tissue factor activity, the procoagulant activity was completely inhibited by incubation with the antibody to tissue factor. In all experiments where tissue factor was generated by the lymphocytes, the material was completely inhibited by the rabbit antihuman tissue factor antibody (Table II) (47, 48) , the site of production of factor VIII is unknown. Perfusion studies of livers and spleens (23) (24) (25) have revealed variable amounts of factor VIII activity in the perfusates. More recent work has shown that the perfusate of rabbit livers contains a material that can stimulate a perfused spleen to release increased levels of factor VIII activity (26) , thus supporting the postulate that the spleen has an active role in the synthesis of factor VIII. Dodds, Raymond, Moynihan, and Fenton have additionally suggested that the hepatic production of factor VIII might be regulated by this same material as indicated by increasing factor VIII activity from the liver with prolonged perfusion (26) . The roles of the liver and spleen in factor VIII synthesis have been further defined by organ transplantation in animals and humans. Variably increased levels of factor VIII activity have been demonstrated in hemophilic subjects who received either liver or spleen transplants (28) (29) (30) (31) . Similarly, infusion of spleen cell concentrates resulted in an increase of factor VIII levels of six patients with hemophilia A (27) . Tissue homogenates from both normal dog kidneys and from a strain of hemophilic dogs have also been shown to have factor VIII-like activity (49) . However, transplantation experiments (50) and perfusion studies (48) have failed to support the thesis that the kidney synthesizes significant quantities of factor VIII. Cell culture studies have described factor VIII synthesis by leukocytes (1), human skin fibroblasts, monkey kidney cells and liver cells (51) , and by splenic macros phages (52). Bouhasin, Monteleone, and Altay reported a case of a patient with hemophilia A who developed acute lymphoblastic leukemia and subsequently had normal factor VIII levels measured (2) . In this study, lymphocytes from seven normal patients were reported to synthesize factor VIII in culture after exposure to PHA, but the leukemic cells were not cultured.
All of the previously described experiments have stimulated great interest in the concept of a multifocal site of origin of factor VIII and supported the older hypothesis that a reticuloendothelial cell was responsible (53) (54) , but the question of storage versus synthesis remains unanswered. With the exception of the previously mentioned study (54) , none of the earlier experiments have proven conclusively that the material assayed was specifically factor VIII. Therefore, it was not surprising that we were unable to demonstrate factor VIII antigen in the lymphocyte preparations in spite of the activity observed in the factor VIII coagulation assay. The evidence that the factor VIII antibody used in our experiments was specific for factor VIII has been summarized elsewhere (44, 45) . These data support the conclusion that the antibody binds to antigen sites on the same molecule as that responsible for factor VIII procoagulant activity.
The data presented here confirm that human blood lymphocytes contain the procoagulant material tissue factor rather than factor VIII. Similar results from human fibroblasts have been presented by Green, Ryan, Malandruccolo, and Nadler (55) . The failure of other investigators to find procoagulant activity in cultures of either rabbit spleen lymphocytes (52) or canine lymphocytes (56, 57) may merely reflect either species differences or methodological variations. We found almost no procoagulant activity released into the supernatant media of the cultures and therefore used lysates of cells exclusively. Previous studies have relied on assays of the supernatants or have utilized incompletely disrupted cells. Further, we cultured the lymphocytes in the presence of either a potent mitogen (PHA) or an antigen (PPD) to which the cells would predictably respond by undergoing blastic transformation. Therefore, we are describing an event that parallels other known functions of stimulated lymphocytes. That is, cells were evaluated not in the dormant state described by other authors but in a dynamic situation perhaps analogous to that described for leukocytes challenged with endotoxin (13, 18) .
That tissue factor is an ubiquitous coagulation protein seems well supported by the finding of stainable tissue factor in the plasma membranes of many types of cells (43) . It appears that interaction of cell membranes with a variety of stimuli (58, 17) permits either the liberation of preformed material or the synthesis of new tissue factor. Lerner, Goldstein, and Cummings (17) and Niemetz (18, 59) have demonstrated that the addition of acinomycin D, puromycin, or cyclohexamide in vitro markedly inhibited the generation of leukocyte procoagulant activity in response to endotoxin. They have suggested that endotoxin stimulates the production of tissue factor in the cells and is dependent upon protein synthesis. In the absence of immunologic or biochemical measures of tissue factor protein it is difficult to evaluate this proposal. An alternative hypothesis suggests that membrane-bound tissue factor is activated by various stimuli so that either the complete protein is formed or, alternatively, an active procoagulant site is exposed by cleavage of a large molecule. Preliminary data suggest that cells without coagulant activity do indeed contain tissue factor antigen.
The pathophysiological importance of lymphocyte tissue factor has yet to be determined, but it is intriguing to consider the various disease entities characterized both by lymphocytic infiltration and pathological thromboses. It is apparent that an understanding of the interaction of various stimuli with cell membranes is crucial for an interpretation of these findings. Studies are presently in progress to define better the character of antigen-lymphocyte interactions with regard to tissue factor elaboration.
